Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

70 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
Wulffelé MG, Kooy A, de Zeeuw D, Stehouwer CD, Gansevoort RT. Wulffelé MG, et al. Among authors: kooy a. J Intern Med. 2004 Jul;256(1):1-14. doi: 10.1111/j.1365-2796.2004.01328.x. J Intern Med. 2004. PMID: 15189360 Review.
We hypothesized that metformin may have a glucose-lowering independent effect on blood pressure and lipid profile. In order to test this hypothesis we systematically reviewed the literature and pooled the data obtained in a meta-analysis. ...When studies were subdiv …
We hypothesized that metformin may have a glucose-lowering independent effect on blood pressure and lipid profile. In order to test t …
Long-term treatment with metformin in type 2 diabetes and methylmalonic acid: Post hoc analysis of a randomized controlled 4.3year trial.
Out M, Kooy A, Lehert P, Schalkwijk CA, Stehouwer CDA. Out M, et al. Among authors: kooy a. J Diabetes Complications. 2018 Feb;32(2):171-178. doi: 10.1016/j.jdiacomp.2017.11.001. Epub 2017 Nov 8. J Diabetes Complications. 2018. PMID: 29174300
AIMS: Metformin treatment is associated with a decrease of serum vitamin B12, but whether this reflects tissue B12 deficiency is controversial. ...In a post hoc analysis, we analyzed the association between metformin, MMA and a validated Neuropathy Score (NPS …
AIMS: Metformin treatment is associated with a decrease of serum vitamin B12, but whether this reflects tissue B12 deficiency is cont …
Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus.
Kooy A, de Jager J, Lehert P, Bets D, Wulffelé MG, Donker AJ, Stehouwer CD. Kooy A, et al. Arch Intern Med. 2009 Mar 23;169(6):616-25. doi: 10.1001/archinternmed.2009.20. Arch Intern Med. 2009. PMID: 19307526 Clinical Trial.
METHODS: We studied 390 patients treated with insulin in the outpatient clinics of 3 hospitals in a randomized, placebo-controlled trial with a follow-up period of 4.3 years. ...In addition, effects on hemoglobin A(1c) (HbA(1c)), insulin requirement, lipid le …
METHODS: We studied 390 patients treated with insulin in the outpatient clinics of 3 hospitals in a randomized, placebo-controlled tr …
Endothelial dysfunction and low-grade inflammation explain much of the excess cardiovascular mortality in individuals with type 2 diabetes: the Hoorn Study.
de Jager J, Dekker JM, Kooy A, Kostense PJ, Nijpels G, Heine RJ, Bouter LM, Stehouwer CD. de Jager J, et al. Among authors: kooy a. Arterioscler Thromb Vasc Biol. 2006 May;26(5):1086-93. doi: 10.1161/01.ATV.0000215951.36219.a4. Epub 2006 Mar 2. Arterioscler Thromb Vasc Biol. 2006. PMID: 16514084
During a follow-up of 11.7 years (median; range 0.5 to 13.2 years), low-grade inflammation was associated with a greater risk of cardiovascular mortality (hazard ratio, 1.43 [95% CI, 1.17 to 1.77] per 1 SD difference). ...
During a follow-up of 11.7 years (median; range 0.5 to 13.2 years), low-grade inflammation was associated with a greater risk …
Combination of insulin and metformin in the treatment of type 2 diabetes.
Wulffelé MG, Kooy A, Lehert P, Bets D, Ogterop JC, Borger van der Burg B, Donker AJ, Stehouwer CD. Wulffelé MG, et al. Among authors: kooy a. Diabetes Care. 2002 Dec;25(12):2133-40. doi: 10.2337/diacare.25.12.2133. Diabetes Care. 2002. PMID: 12453950 Clinical Trial.
A total of 390 patients whose type 2 diabetes was controlled with insulin therapy completed a randomized controlled double-blind trial with a planned interim analysis after 16 weeks of treatment. ...
A total of 390 patients whose type 2 diabetes was controlled with insulin therapy completed a randomized controlled double-bli
Metformin-associated prevention of weight gain in insulin-treated type 2 diabetic patients cannot be explained by decreased energy intake: A post hoc analysis of a randomized placebo-controlled 4.3-year trial.
Out M, Miedema I, Jager-Wittenaar H, van der Schans C, Krijnen W, Lehert P, Stehouwer C, Kooy A. Out M, et al. Among authors: kooy a. Diabetes Obes Metab. 2018 Jan;20(1):219-223. doi: 10.1111/dom.13054. Epub 2017 Sep 14. Diabetes Obes Metab. 2018. PMID: 28681986 Clinical Trial.
Linear mixed models did not show a significant effect of energy intake as explanation for the difference in weight gain between the groups (F-value, 0.1; df = 1; P = .82). ...
Linear mixed models did not show a significant effect of energy intake as explanation for the difference in weight gain between the g …
Metformin and β-cell function in insulin-treated patients with type 2 diabetes: A randomized placebo-controlled 4.3-year trial.
Top W, Stehouwer C, Lehert P, Kooy A. Top W, et al. Among authors: kooy a. Diabetes Obes Metab. 2018 Mar;20(3):730-733. doi: 10.1111/dom.13123. Epub 2017 Oct 27. Diabetes Obes Metab. 2018. PMID: 28967181 Clinical Trial.
We analysed the results with a general linear mixed model. Baseline FCPGR was 5.27 (95% CI, 4.83 - 5.71). Compared to placebo, FCPGR increased in the metformin group with 1.48 (95% CI, 1.09 - 1.87, P < 0.001). The DI showed comparable results with a treatment eff …
We analysed the results with a general linear mixed model. Baseline FCPGR was 5.27 (95% CI, 4.83 - 5.71). Compared to placebo, FCPGR …
Long-term treatment with metformin in type 2 diabetes and vitamin D levels: A post-hoc analysis of a randomized placebo-controlled trial.
Out M, Top WMC, Lehert P, Schalkwijk CA, Stehouwer CDA, Kooy A. Out M, et al. Among authors: kooy a. Diabetes Obes Metab. 2018 Aug;20(8):1951-1956. doi: 10.1111/dom.13327. Epub 2018 May 14. Diabetes Obes Metab. 2018. PMID: 29667290 Clinical Trial.
In a post-hoc analysis, we examined changes in the combined levels of 25(OH)D(2) and 25(OH)D(3) at 4 and 16 months during the study. ...Metformin was associated with a small increase of 25(OH)D(2) (coefficient: 1.012 per month; 95% CI: 1.003-1.021, P = .008). Howeve …
In a post-hoc analysis, we examined changes in the combined levels of 25(OH)D(2) and 25(OH)D(3) at 4 and 16 months during the study. …
Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin.
Zhou K, Yee SW, Seiser EL, van Leeuwen N, Tavendale R, Bennett AJ, Groves CJ, Coleman RL, van der Heijden AA, Beulens JW, de Keyser CE, Zaharenko L, Rotroff DM, Out M, Jablonski KA, Chen L, Javorský M, Židzik J, Levin AM, Williams LK, Dujic T, Semiz S, Kubo M, Chien HC, Maeda S, Witte JS, Wu L, Tkáč I, Kooy A, van Schaik RHN, Stehouwer CDA, Logie L; MetGen Investigators; DPP Investigators; ACCORD Investigators, Sutherland C, Klovins J, Pirags V, Hofman A, Stricker BH, Motsinger-Reif AA, Wagner MJ, Innocenti F, 't Hart LM, Holman RR, McCarthy MI, Hedderson MM, Palmer CNA, Florez JC, Giacomini KM, Pearson ER. Zhou K, et al. Among authors: kooy a. Nat Genet. 2016 Sep;48(9):1055-1059. doi: 10.1038/ng.3632. Epub 2016 Aug 8. Nat Genet. 2016. PMID: 27500523 Free PMC article.
Among obese individuals, C-allele homozygotes at rs8192675 had a 0.33% (3.6 mmol/mol) greater absolute HbA1c reduction than T-allele homozygotes. This was about half the effect seen with the addition of a DPP-4 inhibitor, and equated to a dose difference of 5 …
Among obese individuals, C-allele homozygotes at rs8192675 had a 0.33% (3.6 mmol/mol) greater absolute HbA1c reduction than T-allele …
70 results
Jump to page
Feedback